Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 6, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 700,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,415.5 pence per share; lowest price paid was 1,400.5 pence per share.
- Treasury Holdings (Settled): 509,147,927 shares, representing 9.16% of total issued share capital.
- Treasury Holdings (Including Unsettled): 511,197,927 shares, representing 10.13% of total voting rights.
- Shares in Issue (Excluding Treasury): 5,047,896,118 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 700,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 10.13% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (509,147,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.13% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Check the remaining authority for share buybacks under the mandate granted on May 5, 2011.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.